226 related articles for article (PubMed ID: 32220971)
1. Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Zenke FT; Zimmermann A; Sirrenberg C; Dahmen H; Kirkin V; Pehl U; Grombacher T; Wilm C; Fuchss T; Amendt C; Vassilev LT; Blaukat A
Mol Cancer Ther; 2020 May; 19(5):1091-1101. PubMed ID: 32220971
[TBL] [Abstract][Full Text] [Related]
2. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814.
Sun Q; Guo Y; Liu X; Czauderna F; Carr MI; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2019 Dec; 17(12):2457-2468. PubMed ID: 31551253
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer.
Gordhandas SB; Manning-Geist B; Henson C; Iyer G; Gardner GJ; Sonoda Y; Moore KN; Aghajanian C; Chui MH; Grisham RN
Sci Rep; 2022 Jan; 12(1):974. PubMed ID: 35046420
[TBL] [Abstract][Full Text] [Related]
5. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors.
Samuels M; Falkenius J; Bar-Ad V; Dunst J; van Triest B; Yachnin J; Rodriguez-Gutierrez A; Kuipers M; You X; Sarholz B; Locatelli G; Becker A; Troost EGC
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):743-756. PubMed ID: 37751793
[TBL] [Abstract][Full Text] [Related]
7. DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.
Jiang Y; Willmore E; Wedge SR; Ryan AJ
Mol Cancer Ther; 2021 Sep; 20(9):1663-1671. PubMed ID: 34158348
[TBL] [Abstract][Full Text] [Related]
8. DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.
Carr MI; Chiu LY; Guo Y; Xu C; Lazorchak AS; Yu H; Qin G; Qi J; Marelli B; Lan Y; Sun Q; Czauderna F; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2022 Apr; 20(4):568-582. PubMed ID: 34980594
[TBL] [Abstract][Full Text] [Related]
9. Different Impacts of DNA-PK and mTOR Kinase Inhibitors in Combination with Ionizing Radiation on HNSCC and Normal Tissue Cells.
Klieber N; Hildebrand LS; Faulhaber E; Symank J; Häck N; Härtl A; Fietkau R; Distel LV
Cells; 2024 Feb; 13(4):. PubMed ID: 38391917
[TBL] [Abstract][Full Text] [Related]
10. Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy.
Matsumoto Y
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457081
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
12. DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia.
Carr MI; Zimmermann A; Chiu LY; Zenke FT; Blaukat A; Vassilev LT
Front Oncol; 2020; 10():127. PubMed ID: 32117773
[TBL] [Abstract][Full Text] [Related]
13. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer.
Smithson M; Irwin RK; Williams G; McLeod MC; Choi EK; Ganguly A; Pepple A; Cho CS; Willey CD; Leopold J; Hardiman KM
Neoplasia; 2022 Mar; 25():53-61. PubMed ID: 35168148
[TBL] [Abstract][Full Text] [Related]
15. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
16. DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer.
Wang M; Chen S; Wei Y; Wei X
Acta Pharm Sin B; 2021 Dec; 11(12):3935-3949. PubMed ID: 35024317
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Lee TW; Wong WW; Dickson BD; Lipert B; Cheng GJ; Hunter FW; Hay MP; Wilson WR
Int J Radiat Biol; 2019 Dec; 95(12):1597-1612. PubMed ID: 31490091
[No Abstract] [Full Text] [Related]
18. NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor.
Yu L; Shang ZF; Hsu FM; Zhang Z; Tumati V; Lin YF; Chen BP; Saha D
Oncotarget; 2015 Feb; 6(6):3848-60. PubMed ID: 25714019
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
